Ausgabe Sonderheft 2/2000
Inhalt (18 Artikel)
Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms
T. N. Chase, J. D. Oh, S. Konitsiotis
Projections from basal ganglia to tegmentum: a subcortical route for explaining the pathophysiology of Parkinson’s disease signs?
P. J. Delwaide, J.-L. Pepin, V. De Pasqua, A. M. de Noordhout
MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies
E. Grünblatt, S. Mandel, M. B. H. Youdim
Risk for Parkinson’s disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET
A. Laihinen, H. Ruottinen, J. O. Rinne, M. Haaparanta, J. Bergman, O. Solin, M. Koskenvuo, R. Marttila, U. K. Rinne
Preclinical (premotor) Parkinson’s disease
E. Ch. Wolters, C. Francot, P. Bergmans, A. Winogrodzka, J. Booij, H. W. Berendse, J. C. Stoof
Thalamic, pallidal, or subthalamic surgery for Parkinson’s disease?
P. Krack, M. Poepping, D. Weinert, B. Schrader, G. Deuschl